Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study Protocol for a Single-center, Randomized, Open-label, Two-formulation, Single-dose, Two-cycle, Double-crossover Fasting Bioequivalence Trial of Hemay005 Tablets in Healthy Subjects

NCT06610903 is registered in ClinicalTrials.gov with Ganzhou Hemay Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT06610903
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06610903 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study Protocol for a Single-center, Randomized, Open-label, Two-formulation, Single-dose, Two-cycle, Double-crossover Fasting Bioequivalence Trial of Hemay005 Tablets in Healthy Subjects
Lead sponsor
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase
Phase 1
Overall status
Completed
Start date
September 15, 2024
Completion date
February 17, 2025
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis